BeiGene, Ltd.
06160
2022 6 30
13.09
571 XIVA
2022 6 30
2022 6 30
2022 2022
2023
2022 8 4
2022 8 31 2022 6 30
1
1995 (Private Securities Litigation
Reform Act of 1995)
10-Q
2022 8 4
Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2022
2022 3.045 1.386
120%
2022
203% 23%
(FDA) (EMA)
2022 8 4
BGNE 06160 688235
2022
(John V. Oyler)
50
ALPINE
(Julia Wang)
3
2022
2022 6 30
57 2021 12 31 66
2022 6 30 3.8
5.714 9,630
9,520 2022 6 30
1.296
5,030
1,760 2022 6 30
8,020
930
2022 6 30 3.416 2021
1.5
2022 6 30 3.045 2021
1.386
2022
1.287
4,240
2022
1.049
7,490
2022 2,950
330
2021 8 2022 1
2022
2,340 1,340
4
2022 6 30 3,710
2021
6.5
2021 3
2021 6 30 1,140
2022 6 30 7.81 2021
6.248
2022 6 30 7,120 2021
3,630
2021 8
2022 1
2022 6 30 3.782 2021
3.561
2022 2021
0 4,500
2022 6 30
3,710 2021 3,020
(SG&A) 2022 6 30
SG&A 3.314 2021 2.323
SG&A
SG&A
SG&A 2022 2021 SG&A
4,420 3,460
2022 6 30 3,540
4.394 7.5% 2021 4.748
2022 6 30 5.714
0.43 (ADS) 5.56 2021
4.803 0.40 ADS 5.23
1.296
5
2022 120%
2022
1.287
203%
8,840 456%
(MCL) (WM)
(MZL)
3,670 39%
2022
1.049
40% (NRDL)
9
(BTK)
BTK
50
25
4,500
(MCL)
FDA
(R/R) (FL)
(CLL) (sNDS)
6
2022 (EHA) 2022
(ASCO) 2 ROSEWOOD (NCT03332017)
R/R FL ROSEWOOD (ORR)
2022 EHA ASCO
WM 3 ASPEN (NCT03053440)
43
WM
IgG4 PD-1
Fcγ
9
30 11,000
(NMPA)
(NPC)
(sBLA) NMPA (CDE)
PD-L1 (G/GEJ)
(NSCLC)
(ESCC) (TGA)
(MHRA)
NSCLC ESCC
2022 (ESMO)
RATIONALE 306 (NCT03783442) 3
ESCC
2022 ASCO
NPC
3 RATIONALE 309 (NCT03924986)
RATIONALE 208 (NCT03419897)
(HCC)
7
2022 EHA BGB-11417 NCT04277637
NCT04771130 BGB-11417 CLL
(AML) BCL-2
BGB-A445 1
(NCT04215978) BGB-A445
OX40
BGB-24714 SMAC
1 (NCT05381909)
BGB-15025
1(HPK1)
BGB-10188
PI3Kδ
BGB-23339 2(TYK2)
BLINCYTO
R/R CD19 B
(ALL)
BGB-11417 R/R
8
Zymeworks
Zymeworks 2022 ASCO 1b /2
zanidatamab
HER2
HER2
100 9.3
52,000 6
2023
10
8,000 2022 GMP
64,000
(InnoRNA) mRNA
Chan Lee Chan Lee
9
FDA CLL (SLL) (sNDA)
(PDUFA) FDA
2023 1
EMA CLL MZL
CLL sNDA
2022 3 ALPINE(NCT03734016)
2022 10
NMPA
PD-L1
(BLA)
TGA
NSCLC ESCC
(NDA)
MHRA
NSCLC ESCC
EMA
NSCLC ESCC
FDA
ESCC BLA
FDA
FDA
10
2023
ESCC HCC 2022
2022
HCC 3
(NCT03412773)
2022
o
NSCLC 3
RATIONALE 303(NCT03358875)
o
NSCLC 1
(NCT04047862)
o
sitravatinib PD-L1
NSCLC 1 (NCT03666143)
o
sitravatinib PD-L1
NSCLC 1 (NCT03666143)
(Ociperlimab)
2022
2022 1 (NCT04047862)
BGB-11417 BCL-2
2022
2022 (NHL)
CLL AML (MM) 1 N C T04883957
NCT04277637 NCT04771130 NCT04973605
11
2022 LBL-007
surzebiclimab(TIM3) LBL-007 LAG-3
1,000
2022 2021
6 30 12 31
$ 5,707,963 $ 6,624,849
172,259 483,113
633,100 587,605
7,378,207 8,645,949
234,355 262,400
454,183 558,055
330,966 407,703
344,779 390,362
565,936 629,678
2,075,663 2,402,962
$ 5,302,544 $ 6,242,987
12
ADS ADS
1,000
6 30 3 6 30 6
2022 2021 2022 2021
$ 304,511 $ 138,624 $ 566,084 $ 244,741
37,061 11,368 82,114 511,123
341,572 149,992 648,198 755,864
71,173 36,263 136,410 68,948
378,207 356,091 768,122 676,817
331,403 232,289 625,976 414,395
188 187 376 375
780,971 624,830 1,530,884 1,160,535
(439,399) (474,838) (882,686) (404,671)
11,431 (4,866) 21,502 (9,045)
(129,617) (867) (117,650) (4,990)
(557,585) (480,571) (978,834) (418,706)
13,864 (230) 26,889 (4,860)
(571,449) (480,341) (1,005,723) (413,846)
$ (0.43) $ (0.40) $ (0.75) $ (0.35)
1,336,463,026 1,194,071,476 1,334,252,648 1,191,521,766
ADS
$ (5.56) $ (5.23) $ (9.80) $ (4.52)
ADS
102,804,848 91,851,652 102,634,819 91,655,520
13
8,500
www.beigene.com.cn
1995 (Private Securities
Litigation Reform Act of 1995)
10-Q
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
14